MoneyWorks4Me

Guj. Themis Biosyn - Quaterly Results

07 Nov 2022 Evaluate
The Sales for the quarter ended September 2022 of Rs. 476.91 millions rose by 36.08% from Rs. 350.47 millions.A comparatively good net profit growth of 35.59% to Rs. 186.99 millions was reported for the quarter ended September 2022 compared to Rs. 137.91 millions of previous same quarter.The company reported a good operating profit of 257.98 millions compared to 191.60 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 476.91 350.47 36.08 926.35 674.87 37.26 1148.54 905.63 26.82
Other Income 13.96 7.15 95.24 28.19 18.48 52.54 40.50 32.67 23.97
PBIDT 257.98 191.60 34.65 500.00 370.17 35.07 620.95 435.95 42.44
Interest 0.42 1.26 -66.67 1.04 3.22 -67.70 8.28 9.81 -15.60
PBDT 257.56 190.34 35.32 498.96 366.95 35.97 612.67 426.14 43.77
Depreciation 5.79 5.77 0.35 11.49 11.18 2.77 22.33 17.32 28.93
PBT 251.77 184.57 36.41 487.47 355.77 37.02 590.34 408.82 44.40
TAX 64.78 46.66 38.83 122.77 88.63 38.52 154.10 107.02 43.99
Deferred Tax 2.66 0.18 1377.78 0.74 -0.24 -408.33 0.72 1.26 -42.86
PAT 186.99 137.91 35.59 364.70 267.14 36.52 436.24 301.80 44.55
Equity 72.64 72.64 0.00 72.64 72.64 0.00 72.64 72.64 0.00
PBIDTM(%) 54.09 54.67 -1.05 53.98 54.85 -1.60 54.06 48.14 12.31
Peers
Company Name CMP
Sun Pharma. Inds. 1783.25
Dr. Reddys Labs. 1202.40
Cipla 1329.50
Lupin 2007.10
Zydus Lifesciences 1154.00
View more..